Abbott's erythromycin caps
Executive Summary
"The Pink Sheet" (Aug. 24, T&G-3) incorrectly reported that no generic version of Parke-Davis' ERYC has been approved. Abbott has been marketing since March an erythromycin 250 capsule product that is rated by FDA to be bioequivalent to the Parke-Davis product.